TRThiago Gorayeb Rebelo

Thiago Gorayeb Rebelo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thiago Gorayeb Rebelo has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention: A systematic review and meta-analysis

    by Francinny Alves Kelly, Luis Henrique Rios Moreira Rêgo, Thiago Gorayeb Rebelo, Raissa Martins da Silva, Fernando Rocha Pessoa, Vladia Falcao

  • Open Access

    HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis

    by Francisco Cezar Aquino Moraes, Luis Henrique Rios Moreira Rego, Thiago Gorayeb Rebelo, Gustavo Tadeu Freitas Uchôa Matheus, Ana C. Melo

    Purpose: Gastric cancer (GC) remains a major global health burden, with poor survival rates. HER2 is a key biomarker for targeted therapy, but discordance between primary tumors and metastases may impact treatment decisions. This meta-analysis evaluated the prevalence and clinical relevance of HER2 status differences between primary gastric cancers and metastatic lesions. Methods: A systematic search of PubMed, Embase, and Cochrane was conducted for studies assessing HER2 status in matched primary and metastatic gastric cancer samples. Pooled proportions and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by metastatic site were performed. Statistical analyses were conducted using R software, version 4.2.3. Results: This meta-analysis included 3,515 patients across 20 studies. The pooled proportion of HER2-positive expression in primary gastric tumors was 13% (95% CI: 12–15%; I 2 = 68.7%), while HER2-negative tumors accounted for 74% (95% CI: 72%-76%; I 2 = 94.9%). In metastatic sites, the overall pooled proportion of HER2-positive lesions was 18% (95% CI: 16%-20%; I 2 = 77.3%), with notable variation across anatomical locations: 38% in lung metastases, 31% in liver metastases, 19% in lymph nodes, and 7% in peritoneum. Conversely, HER2-negative metastases accounted for 82% overall (95% CI: 80%-84%; I 2 = 78.2%), with proportions of 93% in peritoneum, 81% lymph nodes, 69% in liver metastases, and 62% in lung. Conclusions: Significant heterogeneity in HER2 expression between primary and metastatic gastric cancer underscores the need for reassessment of HER2 status in metastatic sites. Relying solely on primary tumor samples may lead to underestimation of HER2 positivity and suboptimal therapeutic decisions. Incorporating site-specific HER2 testing into clinical practice may enhance patient selection for HER2-targeted therapies and improve treatment outcomes. Graphic


  • Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis

    by Brenda Luana Rocha Soares Menegat, Ana Luíza Rocha Soares Menegat, Maria Victória Ferreira Piccoli, Luana Diniz Guerra Braz, Thiago Gorayeb Rebelo, Francisco Cezar Aquino de Moraes

    Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving pathological complete response (pCR) rates of 30%. We compared neoadjuvant treatments for early-stage TNBC using a systematic review and network meta-analysis (NMA). PubMed, EMBASE, and Cochrane were searched for randomized and observational studies of neoadjuvant treatment in TNBC. Odds ratios (OR) with 95% confidence intervals were pooled using a random-effects model. Certainty of evidence was assessed with GRADE. Statistical analyses were performed using RStudio. Thirty-seven studies with 7.683 patients were included. Twenty-five treatment nodes were formed, with paclitaxel (P) or docetaxel (D) + anthracycline - based (A) chemotherapy as the main comparator. Compared with PA-based + cyclophosphamide, higher pCR rates were observed with PA-based + carboplatin + pembrolizumab + cyclophosphamide (OR 3,04) and PA - based + carboplatin + veliparib + cyclophosphamide (OR 2,67). When DA-based + cyclophosphamide was the comparator, DA-based + cyclophosphamide + bevacizumab (OR 1,67) increased pCR. The SUCRA ranked PA-based + carboplatin + pembrolizumab, paclitaxel + carboplatin + atezolizumab, and DA-based + lobaplatin as most effective. Platinum agents, PARP inhibitors, and immune checkpoint inhibitors were associated with higher pCR rates in early-stage TNBC. CRD42025640277.

  • Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis

    by Ana Luíza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Luana Diniz Guerra Braz, Maria Victória Ferreira Piccoli, Thiago Gorayeb Rebelo, Francisco Cezar Aquino de Moraes

    1. Urothelial carcinoma (UC) is a heterogeneous group of malignancies arising from the urothelial lining of the urinary tract, with bladder cancer accounting for approximately 90% of cases, followe...